How is Invokana performing

in Mexico in 2017?
Version 3
Job 17-028947

Prepared for: Eduardo Tanoue

Janssen

Prepared by: Arturo Giron

Account Director, Ipsos Healthcare
Mexico
+52 (55) 1101-1897
arturo.giron@ipsos.com
April 19th, 2017

© 2017 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information
and may not be disclosed or reproduced without the prior written consent of Ipsos.
 Warning

This is a confidential document since it is an Industrial Property of Ipsos.

Its partial or total disclosure as well as its reproduction are forbidden.
This proposal includes 19 pages and was submitted April 19th, 2017.

Confidentiality

The market research study will be conducted within the most strict professional ethic;
its results are confidential and for the exclusive use of Janssen.

2
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Contents
1. Executive Summary
2. Context
a) Current Situation & Complication
b) Business Question
c) Research Objectives
3. Methodology
a) Methodology and Sample Sizes
4. Deliverables
a) Deliverable examples
6. Timings & Investment
7. Aspects to Consider
8. Contractual Terms
9. Ipsos Team
10. Why Ipsos?

3
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Executive Summary
Business Question • How to optimize the strategy of the Invokana franchise in Mexico?

• Understand awareness and attitudes of healthcare professionals towards SGLT-2,

Objectives: both for therapy class and individual agents.

Methodological
• Quantitative Study
Approach

• Face to face interviews among Physicians, to be executed at physicians’ offices,

Research Focus using a 45-minute structured questionnaire. 2 waves will be executed.

• Endocrinologists, Internists and GP’s, from Janssen’s database, with 3 to 30 years

Sample Composition experience in their specialty, from Mexico. 150 interviews.

Timings & Investment • USD $43,650 + 16% VAT

• 10 weeks after fieldwork start by wave.

4
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Janssen recently launched Invokana and
Invokana Duo in Mexico, and requires
understanding their performance in terms of
awareness, usage and attitudes towards the
brands and other SGLT-2 in the market.
Measurement of these indicators have
already began in 2015, and these are the 5th
and 6th waves for Mexico.

5
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Study Objectives
Business Question:
How to optimize the strategy of the Invokana franchise in Mexico?

Research Overall Objective:

Understand awareness and attitudes of healthcare professionals
towards SGLT-2, both for therapy class and individual agents.

This research is aimed to achieve the following

strategic objectives:

Objective 1: Objective 2:
To understand the market and physicians To understand the drivers and barriers of this market,
prescription behavior as well as reasons for preference

Action Standard: Determine potential strategies to apply for the Invokana

franchise.
6
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Specific Objectives

• Awareness, perception and usage of T2D treatments,

particularly for non-insulin dependent, anti-diabetes
treatments (including SGLT-2).
• Understand physicians awareness about specific agents in
new kinds of treatments (SGLT-2, DPP-IV and GLP-1)
• Identify opportune information to maximize Invokana /
Vokanamet presentation and promotional activities.

7
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Methodology
In order to achieve these objectives, Ipsos proposes a Quantitative study:

Methodology:
Face to face interviews in Mexico, among Physicians, to be executed at physicians’ offices, using a
45-minute structured questionnaire. 2 waves will be executed.

Target:
Endocrinologists, Internists and GP’s, from Janssen’s database, with 3 to 30 years experience in
their specialty, from Mexico.
Sample Size:
The following number of interviews will be executed, per wave:

Target per wave Mexico

Endocrinologists / Diabetologists 30
IM’s 30
GP’s 90
Total 150

8
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Deliverables

The research considers:

• An individual report by wave, in PowerPoint format in English, including detailed

results, comparison to previous waves as well as recommendations and conclusions.
• One results presentation by wave at Janssen offices in Mexico City.

* Additional requests might impact delivery timings and pricing of the

study.

* Deliverables are subject to data confidentiality warranties.

9
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Deliverable Examples

10
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Investment
Investment for this study is as follows:

Investment Investment
Country USD USD
Per wave 2 waves
Mexico – 150 F2F interviews USD $22,500 USD $45,000
Price with additional 3% discount USD $43,650

NOTES:
•Investment for this project maintains same prices as 2016, which included a 10% discount.
•This proposal considers invoicing from Ipsos Mexico to Janssen subsidiary in Panama, and does not include 16% VAT.
•Ipsos Mexico will coordinate and manage the execution of the project in Mexico and Argentina, while Ipsos Brazil will manage and coordinate
the execution of the Brazil leg.
•This economic proposal is effective through 60 days from the date stated in the cover sheet.
•50% will be paid upon fieldwork start, and the remaining 50% upon results delivery, by country.

11
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Timings
Estimated times wave are:

Weeks
1 2 3 4 5 6 7 8 9 10 11 12
Project Approval &
Kick-off meeting
Set up & Questionnaire
Development

Fieldwork Mexico: 6 weeks

Data Processing &

Analysis

Final Report

Results Presentations

12
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Aspects to Consider – LFPDPPP

• Janssen’s BDDP reception must be conducted through the secure channels set out in Ipsos Safety Policies (share
point, SFTP, etc.)
• Janssen is responsible for personal data and Ipsos assumes the character of agent in charge, reason why it must
handle personal data delivered by Janssen, on behalf of Janssen, and according to its instructions.
• Hence, Ipsos undertakes:
– To handle the personal data in accordance to Janssen´s instructions only;
– Not to use the personal data for purposes different from those intended in the Privacy Notice(s) issued by Janssen. E.g.,
photographs, advertising recordings, etc.;
– To keep the confidentiality regarding personal data of the owners subject to treatment; and
– No to transfer owners’ personal data unless communication is the result from outsourcing, in compliance with the provisions
of the LFPDPPP and is ruling code, or whenever the competent authority so requests.
• The data bases provided by Janssen to Ipsos must include only the necessary data for conducting the research,
i.e., for contacting people:
 Name
 Telephone number
 Address

13
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Contract Stipulations
A. This proposal investment is valid through 60 calendar days from this proposal delivery date.
B. Should economic conditions foreseen by the Federal Government change, deadlines and costs shall be reviewed.
C. Cancellation policies:
-If the research is cancelled after its approval, but before questionnaire’s approval, the client shall be charged 5% of study’s
total cost.
-If the research is cancelled after questionnaire’s approval, but before fieldwork starts, the client shall be charged 10% of
study’s total cost.
-If the research is cancelled after fieldwork starts, the client shall be charged 10% of study’s total cost plus all incurred costs
during fieldwork and up to the date of cancellation.
D. Unless otherwise stated, all data collected from the research shall be considered as client’s property and will not be used by
IPSOS for any other proposal; nor will they be disclosed to any third party without written consent from Janssen. Likewise,
IPSOS will not disclose any supplementary information which the client should have provided (materials, products, lists,
databases, etc.) for research development, since they will be considered as confidential.
E. Unless otherwise stated, study’s deliverables shall be submitted in Spanish in a PowerPoint format.
F. The client will comply with stipulations and responsibilities stated in the Ley Federal de Protección de Datos Personales
(Federal Law for the Protection of Personal Data).
G. IPSOS is entitled to outsource third parties’ services (filed data collection, among others) deemed necessary by IPSOS for the
development and execution of the market research services.
H. The client expressly acknowledges and accepts that any requested change of the current proposal, including namely but not
limited to the structure, methodology, delivery, presentation, language, approach, or sample, shall accordingly modify both
the deadlines and price.

14
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Ipsos Team
Laura Romero
Ipsos Healthcare Mexico Director
Laura holds a degree in Pharmaceutical Chemistry.
She has experience in Healthcare and FMCG markets
from the R&D and market research areas. As
Healthcare Director, she is in charge of very
important clients as well as data construction and
client service. Her main experience is in Primary Care
and Specialty division; i.e. Cardiometabolics,
Immunology, Biological Therapies, Oncology and
Women Health.
Laura joined Ipsos in 2008. Previously, she worked at
P&G (R&D / CMK) and Pearson (Market Research).
She has experienced in regional projects for Primary
Care, Immunology, and Oncology.
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
Arturo Giron
Ipsos Healthcare Mexico Account Director
Arturo is currently working as a highly experienced
researcher (over 10 years) with 2 years in the Health
sector in Mexico and LatAm. He has previously
worked for other market research agencies and large
appliances companies.
Arturo is widely experienced in managing
quantitative and qualitative studies in different
therapeutic areas, such as oncology, virology,
diabetes, immunology, primary sector, medical
devices, etc., showing great knowledge of the
different stakeholders. He focuses particularly on
some brand equity-related methodologies.
He holds a degree in Marketing (ITESM-CEM).
15
 Why Ipsos?

3. Experts in data
2. Extensive integration as well
background in as providing
1. Leadership and Diabetes, covering relevant and useful
wide knowledge of all aspects of the information for the
the health industry condition and decision-making
worldwide treatment process

16
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 THANK
Laura Romero Arturo Girón
laura.romero@ipsos.com arturo.giron@ipsos.com

17
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 © Ipsos 2017 – All rights reserved.
This proposal constitutes the sole and exclusive property of
Ipsos. Ipsos retains all copyright and other rights over,
without limitations, Ipsos’ trademarks, technologies,
methodologies, analysis and know-how included or arising
out of this proposal. The addressee of this proposal
undertakes to maintain it confidential and not to disclose all
or part of its content to any third party the without prior
written consent of Ipsos. The addressee undertakes to use
this proposal solely for its own needs (and the needs of its
affiliated companies, as the case may be), only for the
purpose of evaluating the proposal for services of Ipsos. No
other use is permitted.

18
17-028947_Invokana_ATU_Mexico_2017_V3_19042017
 Certificaciones
IPSOS como miembro fundador de la AMAI (Asociación Mexicana de Agencias de
Inteligencia de Mercado y Opinión Pública), está certificado en Código de Ética y ESIMM
(Estándar de Servicio de Investigación de Mercados en México) un sistema de
aseguramiento de calidad, que recupera estándares internacionales y establece los
requisitos mínimos de la industria.

Metodologías certificadas:

 ESIMM: Cualitativos, Sindicados, F2F, CATI y

Mystery Shopping.

 ISO 9001:2008 e ISO 20252:2012:

Comercialización, Desarrollo, Aplicación e Interpretación
de Estudios de Investigación de Mercado en Metodologías
Cualitativas, Cuantitativas, CATI, Mystery Shopping,
Sindicados, Estudios de Opinión con sus Procesos de Análisis.

Adicionalmente estamos apegados a los estándares de calidad de ESOMAR y CASRO.

Contamos con el distintivo de ESR (Empresa Socialmente Responsable).

19
17-028947_Invokana_ATU_Mexico_2017_V3_19042017